Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633241 | 0.94 | OPRK1 (0.48) | DRD2DRD3PLAUHRH3OPRK1 | |
| SCHEMBL5633087 | 0.86 | OPRK1 (0.46) | DRD2DRD3PLAUHRH3OPRK1 | |
| SCHEMBL4776245 | 0.85 | OPRK1 (0.53) | DRD2DRD3PLAUOPRK1MAPT | |
| SCHEMBL354877 | 0.83 | OPRK1 (0.50) | DRD2DRD3PLAUHRH3OPRK1 | |
| SCHEMBL354878 | 0.83 | OPRK1 (0.50) | DRD2DRD3PLAUHRH3OPRK1 | |
| SCHEMBL4795153 | 0.82 | SMN1; SMN2 (0.51) | PLAUHRH3OPRK1KCNH2MCHR1 | |
| SCHEMBL5633787 | 0.82 | OPRK1 (0.50) | DRD2DRD3PLAUHRH3OPRK1 | |
| SCHEMBL13189373 | 0.82 | FAAH (0.47) | HRH3ALDH1A1ACHE | |
| SCHEMBL354963 | 0.82 | OPRK1 (0.49) | DRD2DRD3PLAUHRH3OPRK1 | |
| SCHEMBL1725336 | 0.82 | OPRK1 (0.49) | DRD2DRD3PLAUHRH3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | DRD2 3363/4885DRD3 3373/4885PLAU 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.